Lymphomas
A newly reported case of pleural tuberculoma, a rare manifestation of tuberculosis, has sparked a diagnostic challenge due to its radiologic similarity to malignant disease. A 31-year-old man with stage IV classical Hodgkin lymphoma was diagnosed with pulmonary tuberculosis, but subsequent imaging revealed a newly developed pleural mass that was
Lymphomas
A newly reported case of pleural tuberculoma, a rare manifestation of tuberculosis, has sparked a diagnostic challenge due to its radiologic similarity to malignant disease. A 31-year-old man with stage IV classical Hodgkin lymphoma was diagnosed with pulmonary tuberculosis, but subsequent imaging revealed a newly developed pleural mass that was
Lymphomas
A recent study published in the Annals of Plastic Surgery investigated the demographic, socioeconomic, and clinical prognostic factors affecting overall survival in patients with primary cutaneous follicle center lymphoma (PCFCL). Researchers from Miami University analyzed data from the National Cancer Database between 2004 and 2020, identifying 1293 patients with PCFCL.
Clinical trials
A new study published in the Haematologica journal provides four-year follow-up results on the efficacy, safety, and pharmacokinetics of tisagenlecleucel treatment for patients with relapsed/refractory follicular lymphoma. The study, led by researchers from the University Teaching Hospital, demonstrates robust and durable responses with tisagenlecleucel and a favorable safety profile,
Lymphomas
A recent study published in the Annals of Plastic Surgery investigated the demographic, socioeconomic, and clinical prognostic factors affecting overall survival in patients with primary cutaneous follicle center lymphoma (PCFCL). Researchers from Miami University analyzed data from the National Cancer Database between 2004 and 2020, identifying 1293 patients with PCFCL.
Clinical trials
A new study published in the Haematologica journal provides four-year follow-up results on the efficacy, safety, and pharmacokinetics of tisagenlecleucel treatment for patients with relapsed/refractory follicular lymphoma. The study, led by researchers from the University Teaching Hospital, demonstrates robust and durable responses with tisagenlecleucel and a favorable safety profile,
Lymphomas
Current study results from the University of Indonesia reveal that gastric lymphoma often presents with non-specific symptoms, leading to delayed diagnosis and potentially life-threatening complications such as gastric outlet obstruction. A 62-year-old male patient's case highlighted the challenges of managing nutritional support and its impact on treatment response
Epstein-Barr virus
Research conducted at Yantai Yuhuangding Hospital in Shandong, People's Republic of China, has shed new light on Epstein-Barr virus-positive follicular lymphoma, a rare and aggressive form of cancer. A case study published in Frontiers in Immunology presents a patient who was treated with R-CHOP chemotherapy combined with rituximab,
Lymphomas
Researchers at Guangxi Medical University Cancer Hospital have conducted a retrospective study to evaluate the efficacy and safety of zanubrutinib combined with salvage chemotherapy in transplant-ineligible patients with relapsed or refractory (R/R) non-GCB diffuse large B-cell lymphoma (DLBCL). The study found that zanubrutinib combined with either bendamustine and rituximab
Pediatrics
Pediatric cutaneous T-cell lymphoproliferative disorders are a complex and poorly understood group of rare diseases, including mycosis fungoides, lymphomatoid papulosis, and primary cutaneous anaplastic large cell lymphoma. Recent research has shed light on the molecular pathogenesis of these disorders, with the identification of recurrent tyrosine kinase gene fusions. A study
Cancer
The federal government of Nigeria has launched a blood-based test, known as Oncoseek, for the early detection of nine high-mortality cancers. The test can identify breast, colorectal, esophageal, liver, lung, lymphoma, ovarian, pancreatic, and stomach cancer. The launch took place during the maiden National Workshop of the National Cancer Control
Cancer
The US FDA has approved label updates for lisocabtagene maraleucel (liso-cel; Breyanzi) in large B-cell lymphoma (LBCL) and other lymphomas, and idecabtagene vicleucel (ide-cel; Abecma) in multiple myeloma, to reduce certain patient monitoring requirements and remove the risk evaluation and mitigation strategy (REMS) programs. According to Bristol Myers Squibb, the
